Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: Phase I trial

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Harada, Hiroyuki ^a   Omura, Ken ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIFE EXPECTANCY; MALE; MAXIMUM TOLERATED DOSE; MEDIAN SURVIVAL TIME; MOUTH SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; NECK METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL SURGERY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR VOLUME; X-RAY COMPUTED TOMOGRAPHY; CLINICAL TRIAL; DRUG COMBINATION; METASTASIS; MIDDLE AGED; MOUTH TUMOR; ORAL DRUG ADMINISTRATION; PREOPERATIVE PERIOD; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM METASTASIS; OXONIC ACID; PREOPERATIVE PERIOD; TEGAFUR; TREATMENT OUTCOME;

EID: 77950929852     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-33     Document Type: Article

References (16)

1. Klug C, Berzaczy D, Voracek M, Millesi W: Preoperative chemoradiotherapy in the management of oral cancer: A review. J Cranio-Maxillofac Surg 2008, 36:75-88.
2. Kirita T, Ohgi K, Shimooka H, Yamanaka Y, Tatebayashi S, Yamamoto K, et al.: Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: An analysis of long-term results. Oral Oncol 1999, 35:597-606.
3. Iguchi H, Kusuki M, Nakamura A, Nishiura H, Kanazawa A, Takayama M, et al.: Concurrent chemoradiotherapy with pirarubicin and 5-fluorouracil for respectable oral and maxillary carcinoma. Acta Otolaryngol Suppl 2004, 554:55-61.
4. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5- fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548-557.
5. Fukushima M: Combines therapy with radiation and S-1, an oral new 5- FU prodrug, is markedly effective against nonsmall cell lung cancer xenografts in mice [Abstract]. Eur J Cancer 2005, 3:343.
6. Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M: Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004, 40: 713-719.
7. Shimosato Y, Oboshii S, Baba K: Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1971, 1:19-35.
8. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53: 457-481.
9. Giralt JL, Gonzalez J, del Campo JM, Maldonado J, Sanz X, Pamias J, et al.: Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer 2000, 89:939-945.
10. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, et al.: Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006, 24:1064-1071.
11. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, et al.: Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2006, 24:4163-4169.
12. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, et al.: Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 2005, 93:884-889.
13. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B: S-1 cooperative study group (Head and Neck Cancer Working Group): Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001, 28:1381-1390.
14. Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, et al.: Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 2009, 64: 945-952.
15. Mandenhall WM: Mandibular osteoradionecrosis. J Clin Oncol 2004, 22:4867-4868.
16. Glanzmann C, Gratz KW: Radionecrosis of the mandibula: A retrospective analysis of the incidence and risk factors. Radiother Oncol 1995, 36:94-100.